Exact Sciences signs research agreements with Broad Institute of MIT and Harvard

Exact Sciences announced separate collaborations with two healthcare organizations in cancer research. The agreements aim to improve patient care by increasing access to genomic information. Exact Sciences and Broad Institute have entered into a 5-year sponsored research agreement and an exclusive license agreement to utilize Minor Allele Enriched Sequencing Through Recognition Oligonucleotides – MAESTRO – as its molecular residual disease diagnostic testing platform. MAESTRO is a next-generation circulating tumor DNA technology that can detect thousands of patient-specific mutations using minimal sequencing and bioinformatics. MAESTRO was developed at the Broad Institute’s Gerstner Center for Cancer Diagnostics which is focused on breakthrough innovations for significant unmet needs in cancer diagnostics. Exact Sciences and Baylor Scott & White – BSW – have entered an agreement to establish the Texas Multicancer Early Detection Registry program, including implementation of Exact Sciences’ MCED test within a subset of BSW primary care clinics. As part of the program, Exact Sciences will generate real-world evidence related to MCED testing in a clinical setting and provide comprehensive support to patients, ordering providers, and clinical staff. The program aims to provide about 50,000 testing opportunities over three years.